CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$48.18 USD
-1.31 (-2.65%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $48.34 +0.16 (0.33%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
CRSP 48.18 -1.31(-2.65%)
Will CRSP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRSP
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why
Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?
Other News for CRSP
Disc Medicine appoints Caffe as CRO
Crispr Therapeutics: Prepare To Be Bored
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Oruka announces closing of merger with ARCA Biopharma
How major US stock indexes fared Wednesday, 8/28/2024